1. MEDIPOST ?! "Care for Patients, Innovations from Research" Making better quality living within reach MEDIPOST is a leading stem cell biotechnology company focused on developing products to meet unmet medical needs such as those related to regenerative or functional recovery of knee articular cartilage, the nervous system, the pulmonary system and hematopoietic transplantation engraftment areas.

1. HISTORY OF MEDIPOST (2000~2006)

1. HISTORY OF MEDIPOST (2007~2010)

1. HISTORY OF MEDIPOST (2011~)

Contents  Overview  Cord blood bank 1. public cord blood bank 2. family cord blood bank  Nutritional supplements

Overview Revolution in medical care MEDIPOST is committed to providing cord blood( 脐带血 / 제대혈 ) banking services an d innovative adult stem cell drugs. Cord blood is the blood remaining in the n ewborn‘s umbilical cord after birth, and it can only be collected at the time of birth.

2-1. PUBLIC CORD BLOOD BANK Public Cord Blood Bank provides a valuable r esource to anyone who may need to undergo a Hematopoietic Stem Cell Transplantation (H SCT) as a result of blood-related diseases. MEDIPOST Public Cord Blood Bank stores over 9,000 units and has provided over 40 0 units of cord blood for successful hemat opoietic stem cell transplantation (HSCT) cases.

2-2. FAMILY CORD BLOOD BANK MEDIPOST's Family Cord Blood Bank - Cel lTree® provides a service for storing your newborn's cord blood exclusively for your family's use. Using the cord blood from a family membe r can increase the efficacy of hematopoieti c stem cell transplantation (HSCT) as muc h as two-fold compared to using the cord blood from an unrelated donor.

MEDIPOST's Family Cord Blood Bank - Cel lTree® stores over 134,000 units of cord bl ood 2-2. FAMILY CORD BLOOD BANK

2.3- Nutritional supplements MEDIPOST provides quality vitamins and nutritional supplements for the benefits of t he pregnant, kids and the elderly.

Investigational New Drug application Testing Animal Testing Human (Phase I, II, III, IV…) Biologic License Application

2.4 - Adult Stem Cell Drugs NEUROSTEM ® Neuro-degenerative disorders. Such as Alzheimer's disease (AD) Currently at clinical trial phase I. PNEUMOSTEM® Pulmonary(Lung) disorders. Such as bronchopulmonary dysplasia (BPD). Currently at clinical trial phase I. PROMOSTEM® Aims to promote early engraftment of donor HSCs following transplantation and improve the success rate of HSCT. CARTISTEM® Stem cell drug for the treatment of Traumatic and Degenerative Osteoarthritis (OA) under license from the Korea Food and Drug Administration (KFDA). Basically stem cells are used from human Umbilical Cord Blood. Use the stem cell obtained from another individual (a term known as 'allogeneic'). Not provoked an immune response when administered into another individual due to use of MSCs. Off-the-Shelf, now available in Korea through the sales and distribution by Dong-A Pharmaceuticals Co., Ltd. Has also received US FDA clearance to conduct Phase I/IIa clinical trials in the US. In Phase III, recovered cartilage of 65 years man.

2.5 - Stem cells known as Mesenchymal Stem Cells (MSCs) hUCB-MSCs Have a special 'immune-privileged' characteristic. From an unrelated donor can be used to treat conditions of any patient. Without concerns of immune-rejection. Privilege of Child

Reference Terms Pictures articleid=1214& ticleid=173& cleid=34123& fasdfasdf

3.1 - hUCB-MSC

3.2 - Stem Cell Manufacturing

3.3 - Stem Cell Efficacy

4.1 - SUBJECT Human cord blood-derived Mesenchymal Stem Cells (hUCB-MSCs)

the blood in umbilical cord many hematopoietic stem cells CORD BLOOD?

4.3 - For what? Treatment -Osteoarthritis -Stroke -Alzheimer’s disease -Bronchopulmonary dysplasia(BPD) Technical development -Improving efficacy of stem cell transplantation